Patents
Literature
173 results about "Drugs preparations" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
High-efficacy glucocorticoid polymorph, preparation method therefor, and use thereof
The present invention relates to a novel polymorph of (1R,2R,3aS,3bR,10aS,10bR,11S,12aS)-5,10b-difluoro-1-(((fluoromethyl)thio)carbonyl)-11-hydroxyl-2,10a,12a-trimethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecylhydrocyclapenta[5,6]napththo[1,2-F]indazole-1-furan-2-carboxylate ester as shown in formula (I), a preparation method therefor, and a use thereof. The crystal form of the present invention has characteristics such as a significant pharmaceutical effect, good stability, high yield, and high purity, and is beneficial for the selection and design of a drug administration route and the determination of a drug preparation process parameter, thereby improving drug production quality.
Owner:ZHEJIANG PALOALTO PHARMA TECH CO LTD
A traditional Chinese medicine composition for treating gestational trophoblastic disease, a preparation method and application thereof, and a pharmaceutical preparation
The application discloses a traditional Chinese medicine composition for treating pregnancy embryo residue, a preparation method and application thereof and a pharmaceutical preparation, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following components: Astragalus membranaceus, Angelica sinensis, Ligusticum chuanxiong, Sparganium stoloniferum, Curcuma zedoaria, Semen Persicae, Herba impatiens, Radix Trichosanthis, Solpugid and Motherwort. Clinical efficacy observation shows that the traditional Chinese medicine composition can effectively promote the discharge of residual tissue, avoid the operation of a palace cleaning operation, shorten the time of vaginal bleeding, promote the repair of endometrium, and has good patient compliance and good tolerance, and no serious adverse reactions are found, and the effective rate is more than 90%. The traditional Chinese medicine composition is based on the theory of monarch, minister and assistant in traditional Chinese medicine, and the components are matched with each other, so that an excellent use effect is achieved.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Crystalline form of bipyrimidine compounds, method of preparation thereof, and use thereof
The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.
Owner:JIANGSU YAHONG MEDITECH CO LTD +1
Sustained-release preparation of indobufen and its preparation method and application
The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.
Owner:TIANJIN LISHENG PHARM CO LTD
A trimetazidine hydrochloride tablet and a preparation process thereof
PendingCN122163560AOrganic active ingredientsSenses disorderPharmaceutical AidsPharmaceutical Substances
The application belongs to the technical field of pharmaceutical preparations, and discloses a trimetazidine hydrochloride tablet and a preparation process thereof.The trimetazidine hydrochloride tablet is composed of trimetazidine hydrochloride, lactose, microcrystalline cellulose, sodium crosslinked carboxymethyl cellulose and other auxiliary materials, and specific auxiliary components are added simultaneously.The preparation process comprises the following steps in sequence: pretreatment of core components, inclusion and dispersion, mixing of soft materials, granulation, drying, total mixing and tablet pressing, and the solubility and dispersibility of the drug are effectively improved.The trimetazidine hydrochloride tablet can realize rapid and sufficient release of the drug, has excellent content uniformity, provides precise and stable dose guarantee for clinical medication, and meets the clinical treatment requirements.
Owner:THE THIRD AFFILIATED HOSPITAL OF HENAN MEDICAL UNIVERSITY
A nano-drug composition, a combined administration system thereof and application thereof
PendingCN122251406Aprevent proliferationPromote secretionOrganic active ingredientsAntibody ingredientsIn vivoPharmaceutical Substances
The present application relates to the field of pharmaceutical preparation and nanomedicine, and particularly relates to a kind of nano-drug composition, its combined drug delivery system and application.The nano-drug composition comprises alpha 1-AR blocker and amphiphilic nano-carrier;The alpha 1-AR blocker is loaded in the hydrophobic core formed by amphiphilic nano-carrier;The alpha 1-AR blocker is selected from one or more of prazosin, terazosin, doxazosin;The average particle size of the nano-drug composition is 220-260 nm, the polydispersity index is less than 0.3, and the encapsulation efficiency is greater than 50%.The nano-drug composition of the present application has dual functions of anti-tumor proliferation and immune microenvironment remodeling, improves the dispersion stability of the drug in physiological medium, effectively reduces the in vivo clearance rate, prolongs the circulation time, and realizes the efficient in vivo delivery of the drug.The preparation process of the nano-preparation is stable and can be produced on a large scale.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Application of psoralen as an Nrf2 agonist in drug preparation
This invention proposes the application of psoralen as an Nrf2 agonist in drug preparation. This invention is the first to discover that psoralen is a specific Nrf2 agonist. Psoralen can directly target and bind to the Nrf2 protein, improving its stability, promoting its phosphorylation and nuclear translocation, thereby activating the Nrf2 signaling pathway, upregulating the expression of downstream antioxidant, anti-inflammatory, and anti-ferroptosis-related proteins, and achieving cell protection and tissue repair functions.
Owner:CENT HOSPITAL OF MINHANG DISTRICT SHANGHAI
A sterile dispenser for pharmaceutical preparations
Owner:CHENGDU SHENGNUO BIOPHARM
Crystalline and amorphous forms of carmixinetosylate
The application discloses a crystal form and amorphous form of carmixin p-toluenesulfonate and a preparation method thereof, relates to the field of medicinal chemistry, and solves the problems of instability, difficulty in scale-up synthesis, and difficulty in drug preparation of carmixin in the prior art. The crystal form and amorphous form of carmixin p-toluenesulfonate disclosed by the application have the characteristics of high purity, high stability, high bioavailability, easy scale-up synthesis, industrialized production and the like, have good moisture-inducing characteristics, and are convenient to store.
Owner:CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
Tumor detection marker and application thereof in drug preparation
PendingCN122081497AIncreased sensitivityimprove featuresOrganic active ingredientsMicrobiological testing/measurementNode metastasisEfficacy
The invention discloses a tumor detection marker and application thereof in medicine preparation, and belongs to the technical field of biomedicine. Clinical sample qRT-PCR (quantitative real-time polymerase chain reaction) shows that ENST00000412203.1 is obviously up-regulated in breast cancer tissues, the area (AUC) under the ROC curve reaches 0.9822, and the diagnosis efficiency is excellent. In addition, the invention further finds that the expression of the polypeptide in lymph node metastasis tissues is obviously improved, and metastasis specificity is displayed. Meanwhile, the expression of ENST00000412203.1 is knocked down through siRNA, it is found that proliferation, migration and invasion of breast cancer cells are remarkably inhibited, and therefore the siRNA can be used for preparing targeted therapy drugs for breast cancer and has important clinical application value.
Owner:REHABILITATION UNIVERSITY QINGDAO CENTRAL HOSPITAL
Applicator and system for administering and dispensing flowable pharmaceutical preparations
PendingUS20260151604A1Organic active ingredientsVolume measurement and fluid deliveryPharmacy medicineTactile sensation
A transdermal delivery apparatus for delivering specific desired quantities of cream-base medicament or any flowable composition is disclosed. The apparatus comprises a revolving platform, a threaded screw-complex, a house, an applicator pad, and a safety cap. The revolving platform produces audible and tactile sensations upon interaction with projections from the house. The threaded screw-complex interacts with an elevator to transport the medicament upwards. The house confines an inner chamber to store the medicament. The applicator pad comprises a center outlet where the composition exits the chamber.
Owner:TICKERWORKS INC
A traditional Chinese medicine composition for treating insomnia based on a modification of Zhang Zhongjing's Wumei Pill
ActiveCN120241942BCoptisMilk protein
This invention provides a composition comprising: 5-15 parts by weight of dried plum, 10-20 parts by weight of cinnamon twig, 10-20 parts by weight of ginseng, 3-8 parts by weight of angelica root, 5-15 parts by weight of asarum, 10-30 parts by weight of dried ginger, 5-15 parts by weight of Sichuan pepper, 5-15 parts by weight of phellodendron bark, 3-8 parts by weight of coptis root, 20-40 parts by weight of bitter wine, 20-30 parts by weight of japonica rice, 10-20 parts by weight of honey, 3-8 parts by weight of lily bulb, 40-60 parts by weight of polygonum multiflorum stem, 40-60 parts by weight of monkey head mushroom, 3-8 parts by weight of polygala root, and 5-15 parts by weight of poria cocos (a traditional Chinese medicine composition). Further, the composition comprises: 20-40 parts by weight of hydrolyzed milk protein, 20-40 parts by weight of fish collagen peptide, and 20-40 parts by weight of soybean peptide (a biological product). This invention also provides pharmaceutical preparations (especially pills) comprising the above composition, biological products, and methods for preparing the same. The composition has a significant effect on improving sleep and has broad application prospects.
Owner:HANGZHOU YUAN HEALTH MANAGEMENT CO LTD
Application of ephedrine in the preparation of drugs for the prevention or treatment of peritoneal fibrosis
This invention discloses the application of ephedrine in the preparation of drugs for the prevention or treatment of peritoneal fibrosis, relating to the field of biomedical technology. The key technical point is: a pharmaceutical preparation for the prevention or treatment of peritoneal fibrosis, the active ingredient of which is ephedrine. This pharmaceutical preparation can achieve preventive and therapeutic effects on peritoneal fibrosis by inhibiting the mesothelial metastatic process (MMT) in peritoneal mesothelial cells, downregulating the expression of fibrosis-related proteins, and improving peritoneal ultrafiltration and solute transport functions, thus providing a new drug option for the treatment of end-stage renal disease patients undergoing peritoneal dialysis.
Owner:SHUNDE HOSPITAL SOUTHERN MEDICAL UNIV (THE FIRST PEOPLES HOSPITAL OF SHUNDE FOSHAN)
Pharmaceuticals #7
Suppresses discoloration of halogenated isoquinoline derivative-containing aqueous compositions during high-temperature storage. To provide technology. [Solution] The following general formula (1) TIFF2026116450000013.tif45170 [In the formula, X represents a halogen atom.] An aqueous composition containing a compound represented by or a salt thereof, or a solvate thereof, is polio A pharmaceutical preparation housed in a container made of refin resin.
Owner:KOWA CO LTD
A compound, a preparation method and application thereof, and a method for preparing a five-membered ring intermediate of sitafloxacin
This invention provides a compound, its preparation method, and its application, as well as a method for preparing a five-membered ring intermediate of sitafloxacin, relating to the field of chemical drug preparation technology. The compound provided by this invention has the structure shown in Formula 1. In this invention, the compound shown in Formula 1 is a novel intermediate. Using it to prepare the five-membered ring intermediate of sitafloxacin (Formula 3) requires no Pd / C and hydrogenation process, and does not form a five-membered ring-opening impurity (Formula 6). The process is simple and suitable for industrial production. This invention provides a method for preparing the five-membered ring intermediate of sitafloxacin (structure shown in Formula 3). In the embodiments of this invention, the prepared five-membered ring intermediate of sitafloxacin with the structure shown in Formula 3 was analyzed by HPLC, and no ring-opening impurity as shown in Formula 6 was detected, with a high yield. Formula 1.
Owner:JIANGXI SHTEC BIOSCIENCE CO LTD +1
Method for obtaining oleocanthal type secoiridoids and for producing respective pharmaceutical preparations
The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.
Owner:OMPHAX SA
An automated nebulizer therapy device and method
This invention relates to the field of medical nebulizer technology, and more particularly to an automated nebulization therapy device and method, comprising a housing, a control system, and a power system. The housing contains a drug preparation chamber, a first nebulization chamber, a second nebulization chamber, and a water chamber. Through the installation of a distilled water pump, a water level monitoring system, a first electric valve, a drug solution level detection system, a drug solution mixing system, a drug solution mixing monitoring system, a second electric valve, and the nebulization system, automated control and nebulization of drug preparation and administration are achieved. This eliminates the need for manual drug preparation by medical personnel, avoiding the problem of poor treatment effects caused by uneven drug preparation and reducing the workload of medical staff. Simultaneously, the device can automatically clean itself, avoiding the impact on the treatment effect of the next patient due to inconsistent cleaning standards during manual cleaning. This solves the problems of high workload for manual drug preparation, poor nebulization effect, and low efficiency caused by uneven drug mixing in existing technologies.
Owner:XI AN JIAOTONG UNIV
A composition, pharmaceutical preparation and use for treating a vascular-bone coupling imbalance disease
The application belongs to the field of treating blood vessel-bone coupling imbalance diseases in traditional Chinese medicine, and particularly relates to a composition for treating blood vessel-bone coupling imbalance diseases, a pharmaceutical preparation and application. Geniposide alone or in combination with crocin I can effectively reduce endothelial cell damage under pathological stimulation conditions, reduce the level of cell apoptosis and the degree of oxidative stress, improve the vascular endothelial function state, and can also significantly inhibit osteoclast differentiation, reduce the number of mature osteoclasts, and reduce bone resorption activity, thereby being conducive to restoring the dynamic balance between bone formation and bone resorption.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES +1
Combination of Anti-her2 antibody-drug conjugate and Anti-trop2 antibody-drug conjugate
PCT designated stageWO2026133218A1Pharmaceutical non-active ingredientsAntineoplastic agentsAntiendomysial antibodiesPharmaceutical drug
A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a drug-linker. An exatecan may be the drug of the drug-linker and the drug-linker may be conjugated to the respective antibody via a thioether bond. Also provided is a therapeutic use and method in which the anti-HER2 ADC and the anti-TROP2 ADC are administered in combination to a subject. The anti-HER2 ADC and anti-TROP2 ADC in combination have excellent anti-cancer properties.
Owner:ASTRAZENECA UK LTD +1
A sustained-release transdermal patch and a preparation process thereof
ActiveCN121731255BOrganic active ingredientsPharmaceutical non-active ingredientsTransdermal patchFt ir spectra
The application discloses a sustained-release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations. The patch is a five-layer composite structure, and the key lies in that: the adhesive layer and the drug depot layer both contain ion pairs of clonidine and organic acid formed in situ under specific solvent and temperature conditions, and the formation of the ion pairs is confirmed by pH value or infrared spectrum; and specific transdermal penetration enhancers are further compounded, so that programmed controlled release is realized through the cooperation of the two layers. The preparation process adopts the sequence of forming ion pairs first and then mixing, realizes coating precision of ±2μm through slit extrusion coating combined with online thickness measurement closed-loop control, adopts gradient drying process with clear temperature zone, air speed and humidity parameters, and carries out real-time quality control based on the online near-infrared spectrum detection of the pre-established PLS regression model. The process can ensure that the patch realizes near-zero-order constant-speed release within 168h, and has the advantages of stable drug release, uniform content, stable quality and high batch consistency.
Owner:SINOPHARM SHANXI RUIFULAI PHARM CO LTD
An abnormality identification and real-time collection system for multi-source heterogeneous medical data
The application discloses a kind of multi-source heterogeneous medical data-oriented exception identification and real-time acquisition system, it is related to medical information technology field;Including event bus module, ensure that the single processing mechanism of data stream is not repeated, no missing, continuously receive the continuous time series data of the physical and chemical properties and the acquisition time, location information of the link of drug preparation, delivery, preservation and clinical use, and the exclusive parameter related to patient individuality.The advantage is that: the present application will be prepared, delivery, save, clinical use whole link heterogeneous data second-level convergence, alignment, make up under the unified event bus framework, form continuous time series flow without repetition, no missing;Through the dynamic mapping of environmental accumulation and drug nature correction coefficient, combined with individual genotype online reverse solving group pharmacokinetics equation, real-time output multi-drug maximum safe superposition dose, supplemented with abstract check trigger data flow playback and periodic online regression update, realize drug safety control.
Owner:HUACHEN HONGYI (BEIJING) TECHNOLOGY CO LTD
A raltitrexed medicated gel stabilized hepatic carcinoma embolism emulsion and a preparation method and application thereof
The application discloses a stable liver cancer embolism emulsion of raltitrexed drug gel and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The emulsion is composed of iodized oil embolism agent and raltitrexed drug gel; the raltitrexed drug gel is a nanofiber network hydrogel formed by self-assembly of raltitrexed molecules in an aqueous phase through ultrasonic treatment, and simultaneously serves as an active pharmaceutical ingredient and an emulsion stabilizer. The iodized oil and the raltitrexed drug gel are physically mixed and injected through a three-way valve to form a stable oil-in-water emulsion or a water-in-oil emulsion, and any additional chemical surfactant or cosolvent is not needed. The emulsion has excellent physical stability, and can effectively solve the problems of easy aggregation and sedimentation of a traditional iodized oil emulsion and increased systemic toxicity caused by drug burst release. The emulsion has good embolism effect and drug release behavior, can significantly inhibit tumor growth, and has a wide clinical transformation prospect.
Owner:XIAMEN HONGPUFU BIOTECHNOLOGY CO LTD
A double-layer targeted sustained-release composition for improving immune function, preparation method and application thereof
PendingCN122351215ACaffeic acidIsochlorogenic acid
The present application relates to the technical field of pharmaceutical compositions, and provides a composition for improving immune function, a preparation and a preparation method and application thereof, comprising: 25-40% of chlorogenic acid, 5-12% of luteolin, 10-20% of isochlorogenic acid A, 3-8% of caffeic acid, 0.5-1% of a targeting ligand, 2-5% of a microecological component, and 5-8% of a nano-carrier, and application of the composition in preparation of medicines, health products and functional foods for improving immune function, and a preparation method of the above-mentioned medicine preparation, comprising the following steps: preparing a core particle; coating the core particle with a sustained-release enteric coating to obtain a microcapsule particle; filling the microcapsule particle into a capsule shell to obtain an enteric capsule; coating the enteric capsule with a stomach-dissolving coating liquid to obtain a capsule preparation; and achieving the effect of improving the whole gastrointestinal immune function by rapidly targeting anti-inflammation in the stomach and continuously targeting regulation in the intestinal tract, and greatly improving the action efficiency and immune regulation effect of the preparation.
Owner:SHANXI QINLING QIYAO COLLABORATIVE INNOVATION CENT CO LTD
Dihydropyridine small molecule compounds, methods of making and use thereof in the preparation of medicaments for treating neuroblastoma
The application relates to a dihydropyridine small-molecule compound and a preparation method and application thereof in preparing a drug for treating neuroblastoma, and belongs to the technical field of drug preparation. The application discloses a dihydropyridine small-molecule compound, a structural formula of which is as shown in the description, which can be used for preparing a drug for treating neuroblastoma with high ALDH18A1 expression, can effectively solve the problems of poor water solubility of YG1702, low inhibition rate of neuroblastoma and other drug application problems, and has a good application prospect.
Owner:CHONGQING UNIV OF TECH +2
Ion pair engineered nanoassemblies inducing type i and ii immunogenic cell death and construction and use thereof
ActiveCN120053640BSmall toxicityeasy to identifyOrganic active ingredientsPhotodynamic therapyAdjuvantImmunogenicity
The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.
Owner:SHENYANG PHARMA UNIV
A minodronic acid tablet and a method for preparing the same
The application belongs to the technical field of pharmaceutical preparations, and discloses a minodronic acid tablet and a preparation method thereof.The tablet provided by the application contains minodronic acid with a specific particle size, hydroxypropyl cellulose and pharmaceutically acceptable excipients, and the synergistic adaptation of the raw materials and the excipients is realized by controlling the particle size of minodronic acid and the suitable weight ratio of minodronic acid and hydroxypropyl cellulose.The application effectively solves the problems of sticking and bumping in the production of minodronic acid tablets, poor dissolution and low bioavailability, and the quality of the preparation is stable and the content is uniform, the preparation process is simple and easy to implement, is suitable for large-scale production, and has biological equivalence with the original research drug, and has a good clinical application prospect.
Owner:SHANDONG NEW TIME PHARMA CO LTD
Fluorinated nanomedicine-loaded thermosensitive hydrogel eye drop, preparation method and application thereof
The present application relates to a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops and its preparation method and application, belong to the new auxiliary material and new dosage form technical field of drug preparation combined treatment, a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops, including temperature-sensitive gel solution and the fluorinated nanomedicine uniformly dispersed in the temperature-sensitive gel solution;The fluorinated nanomedicine is the nanometer assembly formed by intermolecular interaction co-assembly of dexamethasone and fluorinated side chain prodrug;The structural formula of the fluorinated side chain prodrug is as shown below.The temperature-sensitive hydrogel eye drops of the present application further regulate iron death by synergistic anti-inflammatory and antioxidant effects, provide new strategy for treating dry eye.
Owner:SHENYANG PHARMA UNIV
An aqueous ophthalmic temperature-sensitive gel for treating myopia and a preparation method thereof
The application relates to the technical field of pharmaceutical preparations, and particularly discloses an aqueous ophthalmic temperature-sensitive gel for treating myopia and a preparation method thereof. The aqueous ophthalmic temperature-sensitive gel comprises pirenzepine, a temperature-sensitive gel matrix, an osmotic pressure regulator, a pH value regulator and water. The aqueous ophthalmic temperature-sensitive gel has temperature-dependent rheological properties: at 25 DEG C, the viscosity is lower than 1000 mPa.s, and the aqueous ophthalmic temperature-sensitive gel is in a liquid state which is easy to instill; at the ocular surface temperature of 34 DEG C, the viscosity rapidly increases to be greater than 10000 mPa.s, and the aqueous ophthalmic temperature-sensitive gel is converted into a gel state which can be retained for a long time. The application effectively solves the problems of short retention time of traditional pirenzepine eye drops, frequent administration, difficulty in instilling conventional gel eye drops and poor comfort by using a temperature-sensitive in-situ gel technology. The preparation can be prepared into single-dose packaging without preservatives, the compliance, safety and comfort of long-term medication of children are improved, and a new solution is provided for the drug treatment of pediatric myopia.
Owner:NANJING ZEQING PHARM TECH CO LTD